Equities

MediciNova Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4875:TYO

MediciNova Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)276.00
  • Today's Change9.00 / 3.37%
  • Shares traded53.10k
  • 1 Year change-3.50%
  • Beta0.8391
Data delayed at least 15 minutes, as of Feb 10 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.

  • Revenue in USD (TTM)257.92k
  • Net income in USD-12.01m
  • Incorporated2000
  • Employees13.00
  • Location
    MediciNova Inc4275 Executive Square, Suite 300LA JOLLA 92037United StatesUSA
  • Phone+1 (858) 373-1500
  • Fax+1 (858) 404-0048
  • Websitehttps://medicinova.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
TMS Co Ltd0.00-670.20m6.50bn18.00--2.17-----15.72-15.720.0065.780.00----0.00-21.59---22.41----------23.99--0.00------31.20------
Cyfuse Biomedical KK-100.00bn-100.00bn6.75bn21.00--2.27----------298.18------------------------5.80--0.3038---10.91---48.03------
Noile-Immune Biotech Inc7.14m-782.47m6.76bn25.00--1.64--945.69-18.07-18.070.16595.160.00160.000.0668285,720.00-17.08---17.32--30.00---10,954.38--60.62--0.00---97.61--14.65------
PRISM BioLab Co Ltd677.33m-833.70m7.17bn35.00--2.64--10.58-22.84-22.8418.5473.590.1779--12.5819,352,290.00-21.90---26.79--39.83---123.09------0.00--121.62--20.56------
Tsubota Laboratory Inc973.21m-172.89m7.25bn17.00--5.61--7.45-6.79-6.7937.6150.080.47330.67264.0057,247,590.00-8.410.1041-12.170.151780.2771.43-17.760.22162.89--0.05860.00101.4925.17132.08132.7026.42--
OncoTherapy Science, Inc.956.86m-824.72m7.53bn47.00--4.11--7.87-2.90-2.903.384.860.54946.2421.5020,358,640.00-47.35-63.66-58.01-77.438.44-0.3852-86.19-184.758.21-567.860.0139--22.9318.8636.71---70.80--
Linical Co Ltd9.87bn-1.19bn7.84bn598.00--1.18--0.7946-52.52-52.52437.00267.760.6226--3.6916,505,640.00-7.482.59-13.504.1921.6129.24-12.023.74----0.258477.26-15.20-0.9283-259.37---42.014.24
Medinet Co Ltd810.29m-1.36bn7.97bn107.00--2.10--9.84-5.15-5.153.0614.270.162814.023.357,572,813.00-27.37-22.42-28.82-23.6413.5417.68-168.10-173.5915.28--0.00--5.440.6867-6.67--10.06--
Chiome Bioscience Inc593.29m-982.78m8.20bn47.00--7.20--13.81-14.48-14.488.7416.390.28284.979.64---46.84-52.22-59.06-64.4159.9357.59-165.65-174.883.99-1,177.610.1891---24.024.293.72------
Chordia Therapeutics Inc0.00-1.46bn8.68bn20.00--3.64-----21.23-21.230.0032.670.00----0.00-46.77---49.97-------------222.950.00------2.26------
BrightPath Biotherapeutics Co Ltd1.11m-1.08bn9.09bn24.00--5.04--8,190.95-11.59-11.590.011713.700.0007----46,250.00-63.35-59.65-74.36-63.7897.6673.74-96,860.36-28,727.67---1,103.910.00--1,473.61-36.871.45---58.41--
Nano Holdings Inc141.92m-757.17m10.91bn20.00--3.91--76.90-10.69-10.692.0136.620.03598.1716.767,095,800.00-18.65-23.68-21.92-25.3772.6482.69-533.54-746.834.10--0.00---19.92-27.80-7.10------
Medicinova Inc40.20m-1.87bn12.56bn13.00--1.98--312.50-38.17-38.170.8196139.710.0049----3,092,263.00-22.73-15.56-24.08-16.17-----4,656.61-1,144.98----0.00---100.00---28.91---39.68--
Kidswell Bio Corp6.61bn281.24m12.90bn37.0039.555.8945.771.956.576.57147.4144.111.264.316.10178,604,300.005.38-16.7510.76-27.0632.3947.464.26-28.291.37--0.3416--109.0336.3798.51--27.20--
Data as of Feb 10 2026. Currency figures normalised to MediciNova Inc's reporting currency: Japanese Yen JPY
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.